RetiredUnitedHealthcarePolicy CS361LA.D

Lower Extremity Prosthetics (for Louisiana Only)

Policy governs coverage and medical necessity determinations for lower extremity prosthetic devices for UnitedHealthcare Community Plan members in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicyLower Extremity Prosthetics (for Louisiana Only)

Policy CodePolicy CS361LA.D

Change TypeRetiredcoding updates

Effective DateNov 1, 2025

Next Review DateN/A

Key ActionUse InterQual Durable Medical Equipment, Prosthetics, Lower Extremity criteria to document medical necessity and verify applicable HCPCS codes and prior authorization requirements before procurement.

SourceLink

POLICY UPDATE CHANGES

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Updated list of applicable HCPCS codes to reflect quarterly edits, adding L5657 and revising descriptions for L5673 and L5679.

Archived previous policy version CS361LA.C as supporting information.

Retired 4/1/2026policy retirement date

Louisianaapplies only to

InterQualInterQual referenced

77 articlesAHRQ evidence synthesis

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

max reported fall reduction with MPK

insufficientpowered MPA evidence

Coverage and Medical Necessity Criteria

Medical necessity (general) / InterQual referral

Covered when ALL of the following are met:

Overall statement: A lower extremity prosthetic for amputations is considered Medically Necessary in certain circumstances; medical necessity clinical coverage criteria are defined by InterQual CP: Durable Medical Equipment, Prosthetics, Lower Extremity.

Refer to the InterQual CP for specific clinical criteria and documentation requirements.

Not medically necessary / Unproven devices

Bone-anchored percutaneous limb prostheses (e.g., OPRA) are unproven and not Medically Necessary due to insufficient evidence of efficacy.

Microprocessor knee — K1/K2 transfemoral/hip-level amputees: Endoskeletal knee-shin system with microprocessor control (swing/stance) is unproven and not Medically Necessary for amputees with functional classification status K1 or K2 when the amputation level is transfemoral (includes knee disarticulation), hip disarticulation, or hemipelvectomy.MFCL K1-K2

Applies to transfemoral, hip disarticulation, or hemipelvectomy levels.

Combined microprocessor ankle-foot with power assist: Combined microprocessor-controlled ankle-foot system with power assist is unproven and not Medically Necessary due to insufficient evidence for transfemoral, transtibial, or hip disarticulation/hemipelvectomy amputation levels.

Applies to transfemoral, transtibial, and hip disarticulation/hemipelvectomy levels.

Bone-anchored prostheses (not clearly supported)

Bone-anchored percutaneous limb prostheses (OPRA/POP): evidence summary and safety concerns

OPRA/POP evidence: Published studies report that bone-anchored percutaneous limb prostheses can restore mobility and improve patient-reported quality of life in selected transfemoral amputees but the evidence is limited in quantity and quality and is associated with frequent and sometimes serious adverse events (superficial and deep infections, implant loosening, mechanical complications, revisions, and fractures).

Multiple small cohort and case series (including long-term follow-up) and IDE studies report both benefits and high complication rates; risk–benefit balance remains unclear and patient selection/counseling is important.

Microprocessor-controlled knee prostheses

Microprocessor-controlled knees (MPKs): evidence supports use in higher-functioning ambulators; evidence limited or equivocal for lower functioning groups.

MPK support for K3–K4: Systematic reviews and comparative studies provide consistent evidence that microprocessor-controlled knees improve function, reduce falls, and increase satisfaction in community ambulators (MFCL K3 and K4).MFCL K3-K4

References include comparative studies and systematic reviews reporting benefits for higher-functioning ambulators.

MPK for K1–K2: Evidence for routine use of MPKs in lower functional classification levels (MFCL K1–K2) is limited and mixed; some small randomized or crossover trials and cohort studies suggest benefit for select K2 individuals but overall generalizability is constrained by small samples and methodological limitations.MFCL K1-K2

Trial fitting and individualized assessment may be used to determine benefit for select K2 patients.

Evidence summaries and guideline recommendations

Clinical findings and guideline recommendations summarized from the literature:

MPK benefit evidence: Clinical trials and systematic reviews report that MPKs can improve functional performance, reduce uncontrolled falls (reported reductions up to approximately 80% in some reviews), and increase patient satisfaction for selected unilateral transfemoral amputees; however, evidence quality and sample sizes vary.

Includes prospective crossover trials and systematic reviews (e.g., Kaufman, Kannenberg, Hahn).

MPA evidence: Evidence for powered microprocessor prosthetic ankles (MPAs) in transtibial amputees is insufficient and mixed; available studies are few, small, and of variable quality with inconsistent outcomes.

Hayes evolving evidence review and small trials report variable patient-reported and biomechanical outcomes.

Guideline recommendation: The VA/DoD 2017 Clinical Practice Guideline recommends microprocessor knee units over non-microprocessor knee units to reduce falls and maximize patient satisfaction (weak recommendation), while noting insufficient evidence to recommend for or against particular socket designs or foot categories.

A bone-anchored percutaneous limb prosthesis (for example, the OPRA Implant System) is designated as unproven and not Medically Necessary for members covered under this Louisiana plan due to insufficient evidence of efficacy. For medical necessity determinations for lower extremity prostheses generally, refer to the InterQual® CP: Durable Medical Equipment, Prosthetics, Lower Extremity as the clinical coverage standard.

Some HCPCS codes in the policy coding lists are marked with an asterisk (*). These codes are not on the State of Louisiana Medicaid Fee Schedule and therefore may not be covered by the State of Louisiana Medicaid Program; providers should verify state fee-schedule applicability prior to procurement or billing.

The policy does not state an explicit coverage exclusion for powered microprocessor ankle-foot devices (MPAs), but it summarizes the literature as showing insufficient evidence to support use of powered MPAs for transtibial (below-knee) amputations. This indicates the current evidence base is inadequate to assert benefit and providers should expect coverage decisions to reflect that uncertainty.

Endoskeletal microprocessor-controlled knee-shin systems (MPKs) are discussed with respect to functional classification. The policy specifies that MPKs with swing/stance microprocessor control are considered not medically necessary for amputees with K1 or K2 functional classification when the level of amputation is transfemoral (above-knee, including knee disarticulation), hip disarticulation, or hemipelvectomy. The document also notes broader evidence supporting MPKs for higher-functioning ambulators (MFCL K3–K4), and that component selection should consider the patient’s MFCL/K-level.

Bone-anchored percutaneous limb prostheses (OPRA/POP) are supported by limited, generally low-quality evidence showing improvements in mobility and quality of life in some cohorts, but the studies report frequent and sometimes serious complications — including superficial and deep infections, mechanical failures, implant loosening, periprosthetic fractures, and high attrition or device removal rates. Because of these safety concerns and the limited quality of the evidence, the policy concludes that routine use is not clearly supported and the devices are considered unproven/not medically necessary for many patients.

For powered microprocessor prosthetic ankles (MPAs) used in transtibial amputations, the policy summarizes available evidence as insufficient. Reviews and small trials identified by the policy (Hayes evolving review; a few small clinical studies) are of limited quality with variable outcomes, and no professional guidelines were identified to support routine adoption for transtibial amputees.

Applicable HCPCS L-codes and Coding Details

K-level classification

Follow-up timepoints reported in AHRQ key questions

Prior Authorization, Documentation, and Provider Guidance

Prior Authorization

Prior Authorization / Coverage May Be Required

Prior authorization or coverage review may be required for non-fee-schedule, advanced, or high-technology prosthetic components. Codes marked with an asterisk (*) in the Applicable Codes list are not on the State of Louisiana Medicaid Fee Schedule and therefore may not be covered by the State program; contact UnitedHealthcare or the state plan administrator to confirm coverage and any prior authorization (PA) requirements.

Non-fee-schedule / advanced components may trigger PA or exclusion from State fee schedule coverage
Verify plan-specific and state-specific coverage rules before ordering high-technology or atypical components

Billing Rule

Verify Applicable HCPCS Codes and PA

Verify and submit applicable HCPCS codes and obtain prior authorization when required. Ensure billing uses the current HCPCS code set and descriptions (updated quarterly); recent updates include addition of L5657 and revised descriptions for L5673 and L5679.

Background and Evidence Summary

Lower extremity prostheses are artificial devices intended to restore normal function after amputation and enable ambulation, activities of daily living, and return to work. Functional classification using the Medicare Functional Classification Levels (K0–K4) is used to stratify ambulatory potential and guide appropriate component selection; documentation of functional goals and K-level is expected when evaluating prosthetic needs.

Key Terms and Classifications

K-levels (Medicare Functional Classification Level)

Use in clinical decision-makingK-levels are used to stratify ambulatory potential and guide component selection (e.g., MPKs more commonly supported for K3-K4).

Examples of interpretationsK1: household ambulator; K2: limited community ambulator; K3: community ambulator; K4: high-activity demands.

Microprocessor Controlled Knee/Ankle — definition

Core descriptionProsthetic components that use embedded microprocessor control and sensors to modulate swing and/or stance phase or to actively change ankle angle (examples include Otto Bock C-Leg, Ossur RheoKnee, Proprio Foot).

Functional intentDesigned to improve gait pattern, safety, stumble recovery, and adapt to variable cadence or sloped surfaces via real-time control algorithms.

Typical features

Policy Changes and Revision Notes

2026-04-01retirementLatest

Policy retired and Louisiana plan membership disenrolled effective April 1, 2026.

2025-11-01coding update

Updated applicable HCPCS code list: added L5657 and revised descriptions for L5673 and L5679.

Policy Summary

PayerUnitedHealthcare

PolicyLower Extremity Prosthetics (for Louisiana Only)

Policy CodePolicy CS361LA.D

Change TypeRetiredcoding updates

Effective DateNov 1, 2025

Next Review DateN/A

SourceLink

On This Page

Recommendation cited to support consideration of MPKs for fall reduction and satisfaction with acknowledgement of evidence limitations.

Confirm current HCPCS codes and descriptions prior to claim submission
Obtain PA for codes if indicated by the member's benefit plan or state rules
Codes added/updated effective 11/01/2025: L5657 added; L5673 and L5679 descriptions revised

Documentation Required

Service Description and Functional Goals

A lower extremity prosthesis is intended to replace a missing limb or part and to restore normal function to permit ambulation and activities of daily living. Documentation should describe the functional goals for the prosthesis (e.g., ambulation on level and uneven surfaces, stair/ramp negotiation, independence with dressing, return to work) and how the selected components are expected to achieve those goals.

Document specific, measurable functional goals and baseline functional status (e.g., MFCL/K-level, walking distance/speed, fall history)
Indicate why chosen components (e.g., microprocessor knee, foot type) are appropriate to meet the member’s goals

Documentation Required

Clinical Evidence to Support MPK Benefit

When requesting a microprocessor-controlled knee (MPK), include clinical evidence that the member is likely to benefit: functional assessments, MFCL/K-level, trial fitting data (if performed), walking speed, fall history, and results of validated outcome measures or patient-reported outcome tools. Trial fittings are often used to determine individual benefit and should be documented when performed.

Include MFCL/K-level and objective functional measures (e.g., walking speed, ADL tests)
Document history of falls or instability if safety benefit is claimed
Provide trial fitting outcomes, duration, and patient-reported improvements when available

Note

Functional-Level-Based Component Selection

Select components based on the member’s functional level. Evidence supports stronger benefit for MPKs in higher-functioning ambulators (K3–K4); evidence for lower-functioning ambulators (K1–K2) is limited and should be supported by individualized assessments or trial fittings.

Use MFCL/K-level to guide component selection (MPKs generally for K3–K4)
For K1–K2 members, document rationale and objective evidence (or trial fitting results) if advanced components are requested

Includes electronic sensors, microprocessors, and may include powered or powered-assist motors for dorsiflexion/plantarflexion or knee control.

Prosthesis — definition

DefinitionA prosthesis is an artificial device used to replace all or part of a missing body part and is intended to restore normal function.

PurposeIntended to restore mobility and enable ambulation on level and uneven surfaces, stair and ramp negotiation, independence with activities of daily living, and return to work when feasible.

Common levelsCommon lower-limb amputation levels include transtibial (below knee, BK) and transfemoral (above knee, AK).

MFCL / K-levels — ambulatory potential

Purpose of MFCL/K-levelsFunctional classification used to describe ambulatory potential and guide prosthetic component selection across studies and clinical practice.

Common clinical interpretationsK2 = limited community ambulator; K3 = community ambulator; K4 = high activity demands.

Use in evidenceMFCL/K-levels are frequently used in clinical trials and systematic reviews to stratify outcomes (e.g., MPK benefit assessed by K-level).

MFCL / K-level — use in studies and clinical stratification

Role in researchMFCL / K-level is used in multiple studies to stratify ambulatory ability and evaluate prosthetic component outcomes (e.g., K2 vs K3 populations in MPK trials).

Examples from trialsKaufman et al. evaluated primarily K2 unilateral transfemoral amputees to assess MPK benefit.

Practical implicationDocumented MFCL/K-level is an evidence-based factor when considering advanced components and trial fittings; include K-level in assessments.

OPRA Implant System — osseointegrated percutaneous prosthetic system

Device nameOPRA Implant System (Osseoanchored Prostheses for the Rehabilitation of Amputees).

DescriptionAn osseointegrated percutaneous prosthetic system composed of parts that allow a prosthesis to attach directly to the femur (thigh bone).

Regulatory statusGranted FDA premarket approval (PMA) on December 18, 2020.